Isis Begins Phase I Hypertriglyceridemia Drug Study

22 December 2010 (Last Updated December 22nd, 2010 18:30)

Isis Pharmaceuticals has initiated a Phase I study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides. ISIS-APOCIIIRx works by inhibiting the production of apolipoprotein C-III (apoC-III), a traditi

Isis Pharmaceuticals has initiated a Phase I study of ISIS-APOCIIIRx, an antisense drug designed to lower triglycerides to treat a variety of diseases associated with elevated triglycerides.

ISIS-APOCIIIRx works by inhibiting the production of apolipoprotein C-III (apoC-III), a traditionally "undruggable" target that plays an important role in the regulation of triglycerides.

Isis Cardiovascular Diseases Drug Discovery Research vice-president Rosanne Crooke said that many of the current therapies designed to lower triglycerides are associated with undesirable side effects such as flushing.

"In preclinical studies, antisense inhibition of apoC-III reduced the target mRNA and protein, lowered triglyceride levels in plasma, mitigated symptoms of metabolic syndrome and decreased atherosclerosis," Crooke added.

Hypertriglyceridemia is a condition characterised by elevated levels of triglycerides, which can result in numerous cardiovascular and metabolic diseases.